$0.00
Register for Meetings
“In The News” & “Cardiovascular Marketplace” Content Access
Listen to Podcasts
Watch On-Demand Content
CardioTube Access
Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference
Access Recorded Interviews
Download PPT Slide Decks
Already have an account? Login Now
$450 Annually
Complimentary subscription to electronic version of the CRM Journal
Access to CRT Meeting Registration Discounts
CRT Premium Content, including on-demand videos and presentation downloads
Nicole Lou, Contributing Writer, MedPage Today
Patients at the highest risk derived the most benefit from aggressive lipid-lowering with PCSK9 inhibition, according to two analyses of the ODYSSEY OUTCOMES trial.
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details